tetano
Editor, Senior Moderator
Clin Infect Dis
. 2021 Dec 3;ciab999.
doi: 10.1093/cid/ciab999. Online ahead of print.
Duration of SARS-CoV-2 Natural Immunity and Protection against the Delta Variant: A Retrospective Cohort Study
Priscilla Kim[SUP] 1 [/SUP], Steven M Gordon[SUP] 2 [/SUP], Megan M Sheehan[SUP] 1 [/SUP], Michael B Rothberg[SUP] 3 [/SUP]
Affiliations
Abstract
Background: Infection with SARS-CoV-2 has been shown to be highly protective against reinfection and symptomatic disease. However, effectiveness against the highly transmissible Delta variant and duration of natural immunity remain unknown.
Methods: This retrospective cohort study included 325,157 patients tested for coronavirus disease 2019 (COVID-19) via polymerase chain reaction (PCR) from 09 March 2020 to 31 December 2020 (Delta variant analysis) and 152,656 patients tested from 09 March 2020 to 30 August 2020 (long-term effectiveness analysis) with subsequent testing through 09 September 2021. The primary outcome was reinfection, defined as a positive PCR test >90 days after initial positive test.
Results: Among 325,157 patients tested before 31 December 2020, 50,327 (15.5%) tested positive. After 01 July 2021 (Delta dominant period), 40 (0.08%) of the initially positive and 1,494 (0.5%) of the initially negative patients tested positive. Protection of prior infection against reinfection with Delta was 85.4% (95% CI, 80.0-89.3). For the long-term effectiveness analysis, among 152,656 patients tested before 30 August 2020, 11,186 (7.3%) tested positive. After at least 90 days, 81 (0.7%) of the initially positive patients and 7,167 (5.1%) of the initially negative patients tested positive. Overall protection of previous infection was 85.7% (95% CI, 82.2-88.5) and lasted up to 13 months. Patients over age 65 had slightly lower protection.
Conclusions: SARS-CoV-2 infection is highly protective against reinfection with the Delta variant. Immunity from prior infection lasts for at least 13 months. Countries facing vaccine shortages should consider delaying vaccinations for previously infected patients to increase access.
Keywords: COVID-19; Delta; natural immunity; protective effectiveness; reinfection.
. 2021 Dec 3;ciab999.
doi: 10.1093/cid/ciab999. Online ahead of print.
Duration of SARS-CoV-2 Natural Immunity and Protection against the Delta Variant: A Retrospective Cohort Study
Priscilla Kim[SUP] 1 [/SUP], Steven M Gordon[SUP] 2 [/SUP], Megan M Sheehan[SUP] 1 [/SUP], Michael B Rothberg[SUP] 3 [/SUP]
Affiliations
- PMID: 34864907
- DOI: 10.1093/cid/ciab999
Abstract
Background: Infection with SARS-CoV-2 has been shown to be highly protective against reinfection and symptomatic disease. However, effectiveness against the highly transmissible Delta variant and duration of natural immunity remain unknown.
Methods: This retrospective cohort study included 325,157 patients tested for coronavirus disease 2019 (COVID-19) via polymerase chain reaction (PCR) from 09 March 2020 to 31 December 2020 (Delta variant analysis) and 152,656 patients tested from 09 March 2020 to 30 August 2020 (long-term effectiveness analysis) with subsequent testing through 09 September 2021. The primary outcome was reinfection, defined as a positive PCR test >90 days after initial positive test.
Results: Among 325,157 patients tested before 31 December 2020, 50,327 (15.5%) tested positive. After 01 July 2021 (Delta dominant period), 40 (0.08%) of the initially positive and 1,494 (0.5%) of the initially negative patients tested positive. Protection of prior infection against reinfection with Delta was 85.4% (95% CI, 80.0-89.3). For the long-term effectiveness analysis, among 152,656 patients tested before 30 August 2020, 11,186 (7.3%) tested positive. After at least 90 days, 81 (0.7%) of the initially positive patients and 7,167 (5.1%) of the initially negative patients tested positive. Overall protection of previous infection was 85.7% (95% CI, 82.2-88.5) and lasted up to 13 months. Patients over age 65 had slightly lower protection.
Conclusions: SARS-CoV-2 infection is highly protective against reinfection with the Delta variant. Immunity from prior infection lasts for at least 13 months. Countries facing vaccine shortages should consider delaying vaccinations for previously infected patients to increase access.
Keywords: COVID-19; Delta; natural immunity; protective effectiveness; reinfection.